MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
178 hedge funds and large institutions have $3.62B invested in MyoKardia, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 53 increasing their positions, 54 reducing their positions, and 14 closing their positions.
186% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 14
42% more capital invested
Capital invested by funds: $2.55B → $3.62B (+$1.07B)
13% more funds holding
Funds holding: 157 → 178 (+21)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 54
39% less call options, than puts
Call options by funds: $15.8M | Put options by funds: $26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$62.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$52.7M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$17.1M |
| 4 |
BlackRock
New York
|
+$15.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$64M |
| 2 |
O
OrbiMed
New York
|
-$45.8M |
| 3 |
HM
HealthCor Management
New York
|
-$14.7M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$12.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$12.4M |
MYOK Hedge Fund Activity: Q4 2019 in Review
178 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q4 2019, worth a combined $3.62B — up 42% from $2.55B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new MYOK positions and 14 closed out — a net gain of 26 holders — while 53 added to existing stakes and 54 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $62.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $64M sold.
- 178 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q4 2019, up from 157 in Q3 2019.
- Funds reported $3.62B of MyoKardia, Inc. Common Stock stock for Q4 2019, up 42% quarter-over-quarter.
- 40 funds opened new MyoKardia, Inc. Common Stock positions in Q4 2019 and 14 closed out, a net change of +26 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q4 2019 was Janus Henderson Group, an estimated $62.1M added.
- The largest MyoKardia, Inc. Common Stock seller in Q4 2019 was PFM Health Sciences, an estimated $64M sold.
Based on aggregated 13F filings for Q4 2019.